Lentiviral Knockdown of Transcription Factor STAT1 in *Peromyscus leucopus* to Assess Its Role in the Restriction of Tick-borne Flaviviruses

Adaeze O. Izuogu and R. Travis Taylor*

Department of Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA

*For correspondence: travis.taylor@utoledo.edu

[Abstract] Cellular infection with tick-borne flaviviruses (TBFVs) results in activation of the interferon (IFN) signaling pathway and subsequent upregulation of numerous genes termed IFN stimulated genes (ISGs) (Schoggins *et al.*, 2011). Many ISGs function to prevent virus pathogenesis by acting in a broad or specific manner through protein-protein interactions (Duggal and Emerman, 2012). The potency of the IFN signaling response determines the outcome of TBFV infection (Best, 2017; Carletti *et al.*, 2017). Interestingly, data from our lab show that TBFV replication is significantly restricted in cells of the reservoir species *Peromyscus leucopus* thereby suggesting a potent antiviral response (Izuogu *et al.*, 2017). We assessed the relative contribution of IFN signaling to resistance in *P. leucopus* by knocking down a major transcription factor in the IFN response pathway. Signal transducer and activator of transcription 1 (STAT1) was specifically targeted in *P. leucopus* cells by shRNA technology. We further tested the impact of gene knockdown on the ability of cells to respond to IFN and restrict virus replication; the results indicate that when STAT1 expression is altered, *P. leucopus* cells have a decreased response to IFN stimulation and are significantly more susceptible to TBFV replication.

Keywords: Interferon, Flavivirus, Restriction, Reservoir host, Antiviral response, Lentiviral, Knockdown, shRNA, STAT1

[Background] IFN signaling is the first line of defense against flaviviruses invading a host cell (Robertson *et al.*, 2009; Lazear and Diamond, 2015). Molecular signatures associated with the virus particles are detected by pattern-recognition receptors (PRRs) which then elicit downstream signaling via transcription factors to release type 1 IFNs from the cell (Kawai and Akira, 2011; Loo and Gale, 2011). Further, the IFN response pathway is initiated by binding of IFN-beta (IFN- β) to its cognate receptor and activation of the JAK-STAT signaling cascade (Loo *et al.*, 2008). STAT1 is a major player in the IFN response pathway and functions within a complex to activate the IFN-stimulated response element (ISRE) promoter in the nucleus (Stark *et al.*, 1998). Ultimately, IFN signaling transcriptionally upregulates numerous host genes that act to curtail infection and limit viral pathogenesis (Liu *et al.*, 2011).

TBFVs contribute to the global burden of disease by causing encephalitis or hemorrhagic fevers in infected individuals. There are about 10,000 cases of TBE annually and disease is endemic to Europe and parts of Asia (Suss, 2008). In recent years, TBFVs have shown emerging nature due to their occurrence in previously unreported regions and re-occurrence in areas of eradication (Robertson *et al.*,

2009; Ebel, 2010). The reason for the increased spread is not known, and treatment for clinically-recognized cases is limited to palliative care (Fernandez-Garcia *et al.*, 2009; Lani *et al.*, 2014). While virus infection in humans and other susceptible species can result in deleterious illness, infection of a natural reservoir host *P. leucopus* remains asymptomatic (Telford *et al.*, 1997; Santos *et al.*, 2016) suggesting that the host could lack relevant proviral factors or express effective antiviral factors. Data from our lab has explored these possibilities and demonstrated that viral restriction in *P. leucopus* cells is mediated by an antiviral response occurring via the IFN signaling cascade (Izuogu *et al.*, 2017). Our studies involved resolving the sequence of antiviral gene homologs in *P. leucopus* and targeting components of the IFN response pathway. Specifically, our study first showed that STAT1 expression was consistently higher in *P. leucopus* cells compared to the susceptible control *M. musculus* following IFN treatment and virus infection (Izuogu *et al.*, 2017). Based on these data, we further assessed the relative role of STAT1 in virus restriction by specific gene knockdown. This protocol describes the technique used to design shRNA to target STAT1, packaging into lentiviruses and cellular transduction to establish *P. leucopus* stable cell lines with diminished STAT1 expression. We further provide details of how these cells were assayed for a loss of restriction following infection with a TBFV, Langat virus (LGTV).

Materials and Reagents

A. Materials

1. Tissue culture plates (Greiner Bio One International, catalog numbers: 657160, 662160, 677180–6, 24, and 48 wells respectively)
2. Tissue culture flasks (Greiner Bio One International, catalog numbers: 658175 and 660175–75 cm² and 175 cm² respectively)
3. Eppendorf tubes (1.5 ml) (USA Scientific, catalog number: 1615-5510)
4. PVDF membranes (Thermo Fisher Scientific, catalog number: 88518)
5. Lightcycler 480 96-well plate (Roche Molecular Systems, catalog number: 04729692001)
6. Labtek slides (Thermo Fisher Scientific, catalog number: 154534)
7. 1.2 ml tubes (USA Scientific, catalog number: 1412-1000)
8. Autoradiography film (McKesson Medical-Surgical, catalog number: EBA45)
9. Coverslips (Fisher Scientific, catalog number: 12-545-88)
10. Reagent reservoir troughs (VistaLab, catalog number: 3054-1001)
11. Cell scraper (Fisher Scientific, catalog number: 08-100-241)
12. Airtight container (Sterilite, catalog number: 1642)
13. XCell4 SureLock Midi SDS-PAGE system (Thermo Fisher Scientific, Invitrogen™, catalog number: WR0100)
14. 20-well Tris-Glycine midi gel (Thermo Fisher Scientific, Invitrogen™, catalog number: WT0102BOX)

B. Cells

1. Human embryonic kidney (HEK)-293T cells (ATCC, catalog number: CRL-3216)
2. HEK-293 cells (ATCC, catalog number: CRL-1573)
3. African green monkey kidney cells–Vero cells (ATCC, catalog number: CCL-81)
4. *P. leucopus* adult skin fibroblast cells (Coriell Institute, catalog number: AG22353)

Note: These cells mammalian cells are maintained in complete DMEM containing 10% fetal bovine serum (FBS, Nalgene, 100 International units of penicillin, 100 µg/ml streptomycin (Thermo Fisher Scientific).

5. One Shot™ TOP10 Chemically-Competent *E. coli* cells (Thermo Fisher Scientific, Invitrogen™, catalog number: C404010)

C. Viruses

Langat virus (LGTV) strain TP21 (kindly provided by Dr. Sonja M. Best, NIAID/NIH)

Note: LGTV is a naturally-attenuated member of the tick-borne flavivirus serocomplex used under biosafety level 2 (BSL2) laboratory conditions. All safety precautions for BSL2 level containment were adhered to.

D. Reagents

1. pLENTI X2- DEST vector (Campeau *et al.*, 2009)
2. Recombinant mouse IFN-β (Pestka Biomedical Laboratories, catalog number: 12405-1)
3. Oligonucleotide primer pairs (see Table 1)
4. RNAi BLOCK-iT U6 RNAi Entry Vector Kit (Thermo Fisher Scientific, Invitrogen™, catalog number: K4945-00)
5. Agarose (BioExpress,, catalog number: E-3120-500)
6. 100 bp DNA ladder (New England Biolabs, catalog number: N3231L)
7. TAE (10x) buffer (Thermo Fisher Scientific, Invitrogen™, catalog number: 15558042)
8. 10x Tris-glycine SDS-PAGE running buffer (Thermo Fisher Scientific, Invitrogen™, catalog number: LC2675)
9. LR Clonase II Enzyme Mix (Thermo Fisher Scientific, catalog number: 11791100)
10. ViraPower™ Lentiviral Packaging Mix (Thermo Fisher Scientific, catalog number: K497500)
11. Lipofectamine 3000 (Thermo Fisher Scientific, Invitrogen™, catalog number: L3000015)
12. Sodium butyrate (Sigma-Aldrich, catalog number: B5887)
13. Lenti-X GoStix (Takara Bio, Clontech, catalog number: 631244)
14. Polybrene (Sigma-Aldrich, catalog number: 107689)
15. Hygromycin B (Thermo Fisher Scientific, Gibco™, catalog number: 10687010)
16. Phosphate buffered saline (PBS) (Thermo Fisher Scientific, Invitrogen™, catalog number: QVC0508) alone or with 0.5% Tween-20 (PBST)
17. iBlot transfer stacks (Thermo Fisher Scientific, Invitrogen™, catalog number: IB4010-01)
18. Antibodies

- a. α -actin (Sigma-Aldrich, catalog number: A5441)
 - b. α -STAT1 (Cell Signaling Technology, catalog number: 9172S, used at 1:1,000) detects phosphorylation of STAT1 at Tyr701
 - c. α -STAT1-P (Cell Signaling Technology, catalog number: 9167S, used at 1:1,000)
 - d. α -LGTV E (provided by Dr. C. Schmaljohn, USAMRIID used at 1:1,000)
 - e. α -LGTV NS3 (as described in Taylor *et al.*, 2011, used at 1:2,000)
 - f. Goat anti-mouse IgG (Thermo Fisher Scientific, catalog number: A28177, used at 1:3,000 for immunoblotting and at 1:1,000 viral for immunofocus assays)
 - g. Rabbit anti-chicken AlexaFluor 594 (Thermo Fisher Scientific, catalog number: A11042, used at 1:1,000)
 - h. Goat anti-mouse AlexaFluor 488 (Thermo Fisher Scientific, catalog number: A11029, used at 1:1,000)
19. ECL Plus (Thermo Fisher Scientific, Pierce™, catalog number: 80196)
 20. RNeasy Mini Kit (QIAGEN, catalog number: 74104)
 21. QuantiTect Reverse Transcription Kit (QIAGEN, catalog number: 205310)
 22. PCR grade water (Thermo Fisher Scientific, Invitrogen™, catalog number: AM9935)
 23. Gene-specific qRT-PCR primers (see Table 2)
 24. FastStart essential DNA Green master (Roche Molecular Systems, catalog number: 06402712001)
 25. Paraformaldehyde 16% w/v (Alfa Aesar, catalog number: 43368)
 26. ProLong Gold Antifade Mountant with DAPI (Thermo Fisher Scientific, Invitrogen™, catalog number: P36931)
 27. Methanol
 28. Opti-MEM reduced serum medium (Thermo Fisher Scientific, catalog number: 31985062)
 29. Tris (Fisher Scientific, catalog number: BP152-5)
 30. Sodium chloride (NaCl) (Gentox, catalog number: 60-037)
 31. Deoxycholate (Sigma-Aldrich, catalog number: D6750)
 32. 10x Tris-glycine buffer (Thermo Fisher Scientific, Invitrogen™, catalog number: LC2672)
 33. Sodium dodecyl sulfate (SDS) (Fisher Scientific, catalog number: BP166-500)
 34. NP-40 (IGEPAL CA-630) (Sigma-Aldrich, catalog number: 542334)
 35. Magnesium chloride hexahydrate ($\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$) (Avantor Performance Materials, MACRON, catalog number: 5958)
 36. Calcium chloride (CaCl_2) (Acros Organics, catalog number: 192735000)
 37. 3,3-Diaminobenzidine HCl (Sigma-Aldrich, catalog number: D5637)
 38. Hydrogen peroxide (H_2O_2) (Sigma-Aldrich, catalog number: H3410)
 39. Glycerol (AMRESCO, catalog number: 0854)
 40. Bromophenol blue (Bio-Rad Laboratories, catalog number: 1610404)
 41. β -Mercaptoethanol (Alfa Aesar, catalog number: J61337)
 42. Non-fat dry milk

43. DMEM (Thermo Fisher Scientific, Gibco™, catalog number: 12100061)
44. Methylcellulose (Fisher Scientific, catalog number: M352-500)
45. Fetal bovine serum (FBS) (Atlanta Biologicals, catalog number: S11550)
46. Triton X-100 (Sigma Aldrich, catalog number: X100)
47. Sodium citrate (Sigma-Aldrich, catalog number: PHR1416)
48. Bovine serum albumin (BSA)
49. Goat serum
50. Quibit DNA BR kit (Thermo Fisher Scientific, Invitrogen™, catalog number: Q32850)
51. Quibit RNA HS kit (Thermo Fisher Scientific, Invitrogen™, catalog number: Q32852)
52. RNase-free DNase set (QIAGEN, catalog number: 79254)
53. Complete EDTA-free protease inhibitor cocktail (Thermo Fisher Scientific, Pierce™, catalog number: A32955)
54. Complete EDTA-free protease inhibitor cocktail (Roche Diagnostics, catalog number: 11873580001)
55. DC Protein assay reagents (Bio-Rad Laboratories, catalog number: 5000116)
56. Radioimmunoprecipitation assay (RIPA) buffer (see Recipes)
57. DNase I buffer (10x) (see Recipes)
58. Peroxidase substrate (prepared fresh) (see Recipes)
59. 6x SDS-PAGE sample buffer (6x SB) (see Recipes)
60. Western blot blocking solution (see Recipes)
61. Culture overlay media (see Recipes)
62. Permeabilization solution (see Recipes)
63. Immunofluorescence assay blocking solution (see Recipes)

Equipment

1. Pipettes (USA Scientific)
2. Transilluminator (Omega Ultra-Lum)
3. Tabletop centrifuge (Eppendorf)
4. iBlot dry blotting transfer machine (Thermo Fisher Scientific)
5. Rocker (Benchmark)
6. Rotator (Bellco Biotechnology)
7. Autoradiography film processor (Kodak)
8. Thermocycler (Roche Lightcycler)
9. Tissue culture incubator (at 37 °C with 5% CO₂) (Thermo Fisher Scientific)
10. Biosafety cabinet
11. Water bath (VWR Scientific)
12. Heating block (at 95 °C) (Fisher Scientific)
13. SDS-PAGE apparatus (Pharmacia Biotech)

14. Refrigerator
15. Vortex (Fisher Scientific)
16. Qubit 2.0 fluorometer (Thermo Fisher Scientific, current model: Qubit 3.0)
17. Confocal microscope (Olympus Life Science)

Software

1. GraphPad Prism 6: <https://www.graphpad.com/scientific-software/prism/>
2. Roche Lightcycler 96 software: https://lifescience.roche.com/en_us/brands/realtime-pcr
3. Invitrogen primer design software: <https://rnaidesigner.thermofisher.com/rnaiexpress/>
4. MacVector software version 12.7: <http://macvector.com/EcoRI/macvector12.7.5installer.html>

Procedure

A. Design and cloning of short hairpin RNA (shRNA) into lentiviral vectors

Our group recently resolved and published the sequence of STAT1 in the reservoir species *P. leucopus* (Izuogu *et al.*, 2017) with accession number KY451962. Based on the gene sequence, the oligonucleotides for knockdown were designed and cloned as described below; A flowchart describing the process of oligonucleotide processing and generation of lentiviral vectors is represented in Figure 1.

Figure 1. Construction of lentiviral plasmids. A. Schematic representation of *P. leucopus* STAT1 showing the regions targeted for knockdown. B. Workflow of procedure to generate lentiviral expression vectors with shRNA to *P. leucopus* STAT1.

1. Upload the complete sequence to the Invitrogen primer design software (or equivalent) and generate oligo candidates for shRNA design. Regions around the beginning, middle and end of the gene are targeted to ensure complete transcript coverage and avoid off-target effects. Candidates selected are shown in Table 1 and Figure 1A.

Table 1. Oligonucleotide sequences utilized for gene knockdown. shRNA top and bottom strand sequences designed to target 3 distinct regions of the *P. leucopus* STAT1 gene. No special conditions were specified in the primer order.

Region	Oligo name	Oligo sequence
1	pI STAT1_shRNA_261_top	CACCGCGCAATCTTCTAGGATAACTCGAAAGTTATC CTAGAAGATTGCGC
1	pI STAT1_shRNA_261_bottom	AAAAGCGCAATCTTCTAGGATAACTTTGAGTTATCC TAGAAGATTGCGC
2	pI STAT1_shRNA_630_top	CACCGGAAGGAGATAATTCACAAGACGAATCTTGTG AATTATCTCCTTCC
2	pI STAT1_shRNA_630_bottom	AAAAGGAAGGAGATAATTCACAAGATTCGTCTTGTG AATTATCTCCTTCC
3	pI STAT1_shRNA_1742_top	CACCGGTGCATCATGGGCTTTATCACGAATGATAAA GCCCATGATGCACC
3	pI STAT1_shRNA_1742_bottom	AAAAGGTGCATCATGGGCTTTATCATTCTGTGATAAA GCCCATGATGCACC
-	GFP_shRNA_top	CACCGCCACAACGTCTATCCATGGCGAACCATGATA TGACGTTGTGGC
-	GFP_shRNA_bottom	AAAAGCCACAACGTCTATCATGGTTCGCCATGATAT AGACGTTGTGCC

2. As a control, design non-specific oligonucleotides to create lentiviral vectors that will not result in knockdown. An shRNA that targets the GFP sequence was used for this purpose in our study (see Table 1). Since GFP is not expressed in the cells of interest, the control cell lines should be transcriptionally equivalent to the background, non-transduced cells.
3. Anneal the top and bottom strands by mixing oligonucleotides in equal proportion (200 μ M each) and subjecting to high temperature (95 $^{\circ}$ C) for 4 min according to the manufacturer's annealing protocol for the BLOCK-iT U6 RNAi Entry Vector Kit (Thermo Fisher scientific). After the heating process, immediately transfer the samples to the bench and allow for cooling to occur slowly. This process will generate double-strand shRNA.
4. To confirm the annealing step, resolve the samples on a 4% agarose gel (immersed in 1x TAE buffer) alongside a 100 bp ladder by adding equal volume of each sample (10 μ l) to single wells and running at 100 V. Transfer the gel to a transilluminator to visualize double-strand oligonucleotides compared to the single-strand samples (Illustrated in Figure 1B).
5. After the double-strand is confirmed by agarose gel electrophoresis, proceed with the annealed samples and ligate the resultant shRNA into the U6 vector to generate an entry vector for further cloning. The U6 vector is contained within the BLOCK-iT U6 RNAi Entry Vector Kit (Thermo Fisher Scientific) and all manufacturers' recommendations were adhered to.

6. Recombine the entry vector into a lentiviral destination vector that can be delivered into mammalian cells. In this study, we utilized the pLenti X2- DEST vector (Campeau *et al.*, 2009) for Gateway cloning with the Gateway LR Clonase II Enzyme Mix according to the manufacturer's protocol with the exception that recombination was allowed to proceed overnight.
7. Transform chemically-competent One Shot™ TOP10 Chemically-Competent *E. coli* bacteria cells with the recombined DNA and select colonies for DNA extraction to obtain pure plasmid DNA.

B. Generation of Lentiviruses

1. Set up 293T cells at 3,000,000 cells per well in a 6-well dish and grow overnight.
2. Transfect cells with purified lentiviral plasmids targeting the individual regions of the gene of interest and the non-specific (GFP) sequence. Importantly, include a pool of DNA containing 1 µg of lentiviral vectors targeting each region into a single transfection tube. Therefore, prepare a single tube for shRNA targeting each region of interest and an additional tube with all shRNA candidates pooled together in one tube.
3. Add 1 µg of ViraPower Lentiviral Packaging Mix along with plasmid DNA and complete transfection using Lipofectamine 3000 Transfection Kit according to the manufacturer's protocol. Pipet slowly onto cells to avoid detachment.
4. At 24 h post-transfection, replace the transfection media with fresh DMEM containing 10 mM sodium butyrate, 2 ml total volume was suitable for a 6-well dish in our studies.
5. Incubate the cells for another 48 h without perturbing the culture dishes.
6. Collect supernatants containing the newly-generated lentiviruses. Confirm the presence of lentiviruses by running a rapid test using Lenti-X GoStix (use 20 µl sample supernatant followed by three drops of the kit running buffer and allow time for bands to develop). Lentiviral supernatants were not filtered.
7. Store the lentivirus stock at -80 °C until needed.

C. Transduction of *P. leucopus* cells with STAT1 shRNA-expressing lentiviruses

1. Set up *P. leucopus* fibroblasts at 300,000 cells per well in 6-well dishes and incubate overnight.
2. Infect the cells with 1 ml of the lentivirus stock and add 8 µg polybrene (diluted from a stock solution prepared in sterile water).
3. At 1 h post-transduction, add another 1 ml of culture medium with 8 µg polybrene. 24 h later, re-transduce the cells and treat with 8 µg polybrene.
4. On day 2, remove the lentiviral inoculum and replace with fresh culture medium.
5. At day 3 post-transduction, add the appropriate antibiotic selection (400 µg/ml hygromycin was used for *P. leucopus* fibroblasts).
6. Maintain the cells in selection for 1 week and sub-clone to obtain clonal cells by splitting single cells into each well of 48-well dishes and observe for cell proliferation in individual wells over

1-2 weeks.

7. Expand clonal cells into large flasks (175 cm²) and proceed to test for gene knockdown.

D. Assessing gene knockdown in transduced cell lines

Our studies have demonstrated that STAT1 expression is upregulated in *P. leucopus* following treatment with IFN- β (Izuogu *et al.*, 2017). Hence, in order to determine if the gene of interest is knocked down, the cells are treated with IFN and probed for gene induction.

1. Set up the STAT1 knockdown (KD) and NS KD *P. leucopus* fibroblasts at 1,000,000 cells per well and incubate overnight.
2. Treat the cells (or not) with 1,000 international units (IU) mouse interferon beta (mIFN- β) for 8 h and harvest samples to test for knockdown as follows:

By SDS-PAGE and Western blot

- a. Remove the cellular supernatant and wash the cells 2 x with PBS buffer.
- b. Add 500 μ l of RIPA buffer (see Recipes) and scrape the cell monolayer gently. Pipet a few times and transfer the sample to Eppendorf tubes.
- c. Incubate the samples with 50 μ l 1x DNase I buffer (see Recipes) for 30 min at 37 °C.
- d. Centrifuge at max speed for 10 min, collect supernatant and mix with 6x SB to achieve 1x SB (see Recipes). Load equal amounts of protein on 10% SDS gels and resolve at 150 V for 1.5 h.
- e. After the electrophoresis step, transfer the proteins to PVDF membranes using the iBLOT transfer apparatus for 7 min.
- f. Incubate the membranes with Western blot blocking solution (see Recipes) while rocking for 1 h at room temperature (RT).
- g. Probe the blots with specific antibodies to STAT1 and phosphorylated STAT1 (STAT1-P) for 16 h at 4 °C on a rocker and wash 3 x in PBST for 5 min.
- h. Incubate with secondary antibodies conjugated to HRP while rocking for 1 h at RT. Wash 3 x in PBST for 10 min.
- i. Perform a final wash with PBS for 5 min, incubate membranes with ECL-plus reagents for an additional 5 min and utilize an automated film processor to visualize protein expression. Figure 2A shows Western blot results for STAT1 KD.

By qRT-PCR

- a. Remove cellular supernatant and wash the cells 2 x in PBS. Harvest cell lysates according to RNA extraction protocol. In this study, cells were collected in 350 μ l of cell lysis buffer (RLT buffer included RNeasy mini kit) and RNA extraction was performed using the RNeasy mini kit according to the manufacturer's protocol, including the DNase treatment step using the RNase-free DNase set (QIAGEN).
- b. Quantify the RNA and normalize the concentration to ensure an equal amount of RNA between all the samples.

- c. Perform cDNA synthesis using an equal amount of RNA template (1 µg was used). Our study utilized the QuantiTect Reverse Transcription Kit according to the manufacturer's protocol.
- d. Make a 1/8 dilution of the samples using PCR-grade water and add 3 µl of each sample to individual wells of a clean, opaque 96-well plate. Add 1 µl each of Fwd. and Rev. primers for a total of 5 µl; primer sequences used to detect *P. leucopus* STAT1 are shown in Table 2. In this study, the FastStart Essential Green Master Enzyme Mix was used and 5 µl of this was added to each sample for the reaction. Thus, the total reaction volume was 10 µl.

Table 2. qRT-PCR primers used to probe for STAT1 and β -actin in *P. leucopus* cells

Primer	Sequence
STAT1 Fwd	GAGAGAACTTCTGGGTCCTAAC
STAT1 Rev	GATCCAAGGCCAGAAGGAAA
pITRIM79 Fwd	CTGGACTCCAAGGAGAAGAATG
pITRIM79 Rev	CTGCTTCACCAGCTCTCTTT
β -ACTIN Fwd	CACACTGTGCCATCTATGA
β -ACTIN Rev	GGATCTTCATGAGGTAGTCTGTC

- e. Run on Lightcycler for 50 cycles and analyze the resultant data. The fold induction of STAT1 in the NS controls was set to 100% and the fold induction in the KD cells was assessed comparative to the NS cells. All data are normalized to β -actin. Figure 2B shows relative STAT1 mRNA expression.

Figure 2. Assessing gene knockdown in transduced cell lines. A. Flow chart and data of Western blot showing decreased expression of STAT1 in *P. leucopus* KD cells expressing

shRNA to positions 261 (STAT1KD #1), 630 (STAT1KD #2) and all 3 positions–261, 630 and 1,742 (STAT1KD All). All further experiments were performed with the 'STAT1 KD All' cells and they are henceforth named as STAT1 KD cells. Samples were probed with antibodies to STAT1, STAT1-P and β -actin. B. Flow chart and data of qRT-PCR showing percentage relative STAT1 mRNA expression in the STATIKD cells compared to the NS control. Asterisks indicate: **** = $P < 0.00001$.

E. Perform a functional assay for IFN response in STAT1 KD cells

Having observed knockdown, we tested the impact of STAT1 KD on the upregulation of an ISG. Data in our lab has identified a homolog of the TBFV restriction factor-tripartite motif protein 79 (TRIM79) and also demonstrated it to be an ISG in *P. leucopus* cells (Taylor *et al.*, 2011). We assayed the fold induction of *P. leucopus* TRIM79 (pTRIM79) in STAT1 KD cells following IFN treatment according to the following protocol:

1. Set up STAT1 KD and NS control cells as in Procedure D, treat with mIFN- β for 8 h and proceed to harvest RNA as described above in the qRT-PCR section.
2. Use an equal amount of RNA as template for cDNA synthesis and perform qRT-PCR reaction using gene-specific primers. Fold induction was assessed relative to untreated cells. We also compared pTRIM79 induction in *P. leucopus* cells with specific lentiviral knockdown to the type 1 IFN receptor (IFNAR1) generated using the same technique outlined above. Data is shown in Figure 3.

Figure 3. qRT-PCR of an ISG pTRIM79 in STAT1 KD cells relative to the NS control. Cells with altered STAT1 (and IFNAR1) expression show significantly less ISG induction suggesting that knockdown has a functional impact on IFN signaling. Mean $\pm$ SD. Asterisks indicate: ** = $P < 0.01$, *** = $P < 0.001$.

F. Test the effect of STAT1 KD on LGTV replication

By immunofluorescence microscopy

1. Set up STAT1 KD and NS cells at 50,000 cells per well in 8-well Labtek slides and incubate overnight.
2. Infect the STAT1 KD and NS cells with LGTV at MOI of 100. Allow a 1 h absorption period and replace the inoculum with 500 µl of fresh culture media.
3. At 72 h post-infection, remove supernatant, wash cells 2 x with PBS and fix for 20 min in 4% paraformaldehyde solution. Add just enough to cover the slides (about 5 ml).
4. Wash 2 x with PBST and permeabilize cells for 5 min. Remove permeabilization solution (see Recipes) and add 3 ml immunofluorescence assay blocking solution (see Recipes) for 1 h at RT. Specific antibodies to LGTV envelope (E), and LGTV non-structural protein 3 (NS3) proteins were used in this study at 1:2,000 dilution.
5. Wash 3 x with PBS and incubate with the appropriate fluorescent secondary antibodies diluted in 3 ml blocking solution for 1 h at RT in the dark. Wash cells 3 x in opaque containers protected from light.
6. Add mounting media containing DAPI—This study utilized 1 ml of the ProLong Gold Anti-Fade Mountant with DAPI added and slides were imaged on an Olympus confocal microscope. Figure 4A includes the confocal image data showing increased viral protein staining in STAT1 KD cells.

By virus titration and immunofocus assay

1. Set up STAT1 KD and NS cells at 100,000 cells per well in 24-well dishes and incubate overnight.
2. Infect cells with LGTV at a multiplicity of infection (MOI) of 10 such that there would be 10 virion particles to each cell in the monolayer. This is calculated as a product of the cell density, desired MOI and number of wells divided by the viral titer to determine the volume of viral stock needed for infection. Inoculate the cells with 250 µl of the virus solution and allow a 1 h absorption period and replace the inoculum with 500 µl of fresh culture media.
3. Collect viral supernatants at 24, 48, and 72 h post-infection in triplicates and store at -80 °C.
4. Set up Vero cells at 200,000 cells per well in 24-well dishes and incubate overnight.
5. Make six 1/10 serial dilutions of each viral supernatant sample in FBS-free DMEM media using the 1.2 ml tubes and add 250 µl of each diluted to fresh Vero cells. Allow a 1 h absorption period and replace the inoculum with 500 µl of fresh culture media containing 2% FBS and 0.8% methylcellulose (culture overlay media).
6. At 4 d post-infection, perform the immunofocus assay as described previously (Taylor *et al.*, 2011; Baker *et al.*, 2013). Briefly, remove the culture overlay media (see Recipes) and wash the cells 2 x with PBS. Fix with 100% methanol for 30 min and wash again with PBS.
7. Incubate for 20 min in Opti-MEM medium and follow up with a virus-specific antibody. In this study, an antibody to detect the LGTV envelope (E) protein was used at 1:1,000. Incubate with

primary antibody for 1 h at 37 °C in an airtight container.

8. Wash cells 2 x with PBS and incubate with the appropriate secondary antibody. Goat anti-mouse IgG antibody was used in this study at 1:1,000. Incubate as in primary antibody and follow with 2 PBS washes.
9. Add the substrate and allow 15 min for foci to develop. Determine the number of focus-forming units (FFU) per ml of viral supernatant and compare virus release in each cell type and condition. Results of STAT1 KD on LGTV infection are shown in Figure 4B.

Figure 4. Determining the impact of STAT1 KD on LGTV infection of *P. leucopus*. A. Visualizing LGTV protein staining in STAT1 KD *P. leucopus* cell lines by immunofluorescence microscopy. Images were captured on an Olympus microscope at 40x magnification showing LGTV E (green), NS3 (red) and nuclei are stained with DAPI (blue). B. Quantifying LGTV replication in *P. leucopus* STAT1 KD cells assessed by performing an immunofocus assay. This assay involves titrating supernatants from the infected clonal cells onto fresh Vero cells and quantifying the resultant foci. Viral titer is indicated as focus forming units (ffu) per ml. Mean $\pm$ SD; Data are from three independent experiments performed in triplicate. Asterisks indicate: * = $P < 0.05$, *** = $P < 0.001$, **** = $P < 0.00001$.

Data analysis

All titration experiments were performed three times in triplicates. Data were analyzed by an unpaired *t*-test or Mann-Whitney U test using GraphPad Prism 6 software as described in Izuogu *et al.*, 2017 (<http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0179781>).

Notes

1. Depending on the application, cDNA samples can be used at higher dilutions for qRT-PCR.
2. When annealing oligonucleotides, rather than transferring the sample tubes to the bench, transfer the entire heat block from the heating system—this will allow cooling to occur at a very slow rate.
3. Vero cells are African green monkey cells which have a defect in interferon secretion thereby making them suitable to count viruses by titration. They also form foci and plaques relatively well.

Recipes

1. Radioimmunoprecipitation assay (RIPA) buffer
 - 50 mM Tris pH 7.5 (100 ml 1 M)
 - 150 mM NaCl (60 ml 5 M)
 - 0.5% deoxycholate (20 g)
 - 0.1% SDS (10 ml 20%)
 - 1% NP-40 (20 ml IGEPAL CA-630)
 - dH₂O (up to 2 L)
2. DNase I buffer (10x)
 - 100 mM Tris-HCl pH 7.5
 - 25 mM MgCl₂
 - 5 mM CaCl₂
3. Peroxidase substrate (prepared fresh)
 - 0.4 mg/ml 3,3-diaminobenzidine HCl
 - 0.45 µl/ml 30% H₂O₂
 - 1x PBS
4. 6x SDS-PAGE sample buffer (6x SB)
 - 375 mM Tris-HCl, pH 6.8
 - 9% SDS
 - 50% glycerol
 - 0.03% bromophenol blue
 - 9% β-mercaptoethanol, fresh

5. Western blot blocking solution
5% non-fat dry milk in PBST
6. Culture overlay media
Complete DMEM supplemented with 0.8% methylcellulose and 2% FBS
7. Permeabilization solution
0.1% Triton X-100 and 0.1% sodium citrate in PBS
8. Immunofluorescence assay blocking solution
0.5% BSA and 1% goat serum in PBS

Acknowledgments

This work is supported by a pilot grant funding from the Lyme Disease Association and the University of Toledo College of Medicine and Life Sciences startup funds (RTT). The protocol and the representative results shown herein were adapted from our published work (Taylor *et al.*, 2011; Izuogu *et al.*, 2017). We thank Dr. Jason Munshi-South and Dr. Stephen Harris for their help in generating the initial nucleotide hits that were used to resolve the STAT1 sequence in *P. leucopus*. We declare no conflicting or competing interests.

References

1. Baker, D. G., Woods T. A., Butchi, N. B., Morgan, T.M., Taylor, R.T., Sunyakumthorn, P., Mukherjee, P., Lubick, K. J., Best, S. M. and Peterson K. E. (2013). [Toll-like receptor 7 suppresses virus replication in neurons but does not affect viral pathogenesis in a mouse model of Langkat virus infection.](#) *J Gen Virol* 94(2): 336-47
2. Best, S. M. (2017). [The many faces of the flavivirus NS5 protein in antagonism of type I interferon signaling.](#) *J Virol* 91(3): e01970-16.
3. Campeau, E., Ruhl, V. E., Rodier, F., Smith, C. L., Rahmberg, B. L., Fuss, J. O., Campisi, J., Yaswen, P., Cooper, P. K. and Kaufman, P. D. (2009). [A versatile viral system for expression and depletion of proteins in mammalian cells.](#) *PLoS One* 4(8): e6529.
4. Carletti, T., Zakaria, M. K. and Marcello, A. (2017). [The host cell response to tick-borne encephalitis virus.](#) *Biochem Biophys Res Commun* 492(4):533-540.
5. Duggal, N. K. and Emerman, M. (2012). [Evolutionary conflicts between viruses and restriction factors shape immunity.](#) *Nat Rev Immunol* 12(10): 687-695.
6. Ebel, G. D. (2010). [Update on Powassan virus: emergence of a North American tick-borne flavivirus.](#) *Annu Rev Entomol* 55: 95-110.
7. Fernandez-Garcia, M. D., Mazzon, M., Jacobs, M. and Amara, A. (2009). [Pathogenesis of flavivirus infections: using and abusing the host cell.](#) *Cell Host Microbe* 5(4): 318-328.
8. Kawai, T. and Akira, S. (2011). [Toll-like receptors and their crosstalk with other innate receptors in infection and immunity.](#) *Immunity* 34(5): 637-650.

9. Lani, R., Moghaddam, E., Haghani, A., Chang, L. Y., AbuBakar, S. and Zandi, K. (2014). [Tick-borne viruses: a review from the perspective of therapeutic approaches](#). *Ticks Tick Borne Dis* 5(5): 457-465.
10. Lazear, H. M. and Diamond, M. S. (2015). [New insights into innate immune restriction of West Nile virus infection](#). *Curr Opin Virol* 11: 1-6.
11. Liu, J., Elmore, J. M., Lin, Z. J. and Coaker, G. (2011). [A receptor-like cytoplasmic kinase phosphorylates the host target RIN4, leading to the activation of a plant innate immune receptor](#). *Cell Host Microbe* 9(2): 137-146.
12. Loo, Y. M., Fornek, J., Crochet, N., Bajwa, G., Perwitasari, O., Martinez-Sobrido, L., Akira, S., Gill, M. A., Garcia-Sastre, A., Katze, M. G. and Gale, M., Jr. (2008). [Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity](#). *J Virol* 82(1): 335-345.
13. Loo, Y. M. and Gale, M., Jr. (2011). [Immune signaling by RIG-I-like receptors](#). *Immunity* 34(5): 680-692.
14. Izuogu, A. O., McNally, K. L., Harris, S. E., Youseff, B. H., Preslold, J. B., Burlak, C., Munshi-South, J., Best, S. M. and Taylor, R. T. (2017). [Interferon signaling in *Peromyscus leucopus* confers a potent and specific restriction to vector-borne flaviviruses](#). *PLoS One* 12(6): e0179781.
15. Robertson, S. J., Mitzel, D. N., Taylor, R. T., Best, S. M. and Bloom, M. E. (2009). [Tick-borne flaviviruses: dissecting host immune responses and virus countermeasures](#). *Immunol Res* 43(1-3): 172-186.
16. Santos, R. I., Hermance, M. E., Gelman, B. B. and Thangamani, S. (2016). [Spinal cord ventral horns and lymphoid organ involvement in powassan virus infection in a mouse model](#). *Viruses* 8(8).
17. Schoggins, J. W., Wilson, S. J., Panis, M., Murphy, M. Y., Jones, C. T., Bieniasz, P. and Rice, C. M. (2011). [A diverse range of gene products are effectors of the type I interferon antiviral response](#). *Nature* 472(7344): 481-485.
18. Stark, G. R., Kerr, I. M., Williams, B. R., Silverman, R. H. and Schreiber, R. D. (1998). [How cells respond to interferons](#). *Annu Rev Biochem* 67: 227-264.
19. Suss, J. (2008). [Tick-borne encephalitis in Europe and beyond--the epidemiological situation as of 2007](#). *Euro Surveill* 13(26).
20. Taylor, R. T., Lubick, K. J., Robertson, S. J., Broughton, J. P., Bloom, M. E., Bresnahan, W. A. and Best, S. M. (2011). [TRIM79 \$\alpha\$, an interferon-stimulated gene product, restricts tick-borne encephalitis virus replication by degrading the viral RNA polymerase](#). *Cell Host Microbe* 10(3): 185-196.
21. Telford, S. R., 3rd, Armstrong, P. M., Katavolos, P., Foppa, I., Garcia, A. S., Wilson, M. L. and Spielman, A. (1997). [A new tick-borne encephalitis-like virus infecting New England deer ticks, *Ixodes dammini*](#). *Emerg Infect Dis* 3(2): 165-170.